Drugs / MSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04377334 | May → Nov 2022 | COVID-19, acute respiratory distress syndrome | University Hospital Tuebingen | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04377334 ↗ |
| Modality | Cell therapy | “allogeneic bone marrow-derived human mesenchymal stem (stromal) cells” NCT04377334 ↗ |
| Route | Other | “infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells” NCT04377334 ↗ |